Cytokinetics Incorporated's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Cytokinetics Incorporated's ROA in the third quarter of 2026?
Cytokinetics Incorporated recorded a cumulative net loss of $-778 million during 12 months ending in the third quarter of 2026, resulting in a negative return on assets (ROA) of -39.43%.

However, within the Healthcare sector 605 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 4072, from total ROA ranking in the second quarter of 2026 at 4717.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	26.97 %	174.83 %	0.68 %	1.55 %	0.01 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-778	-894	-830	-785	-752
Return On Assets (TTM)	-39.43 %	-47.65 %	-61.9 %	-58.66 %	-56.42 %
CYTK's Total Ranking	# 4072	# 4717	# 4122	# 4054	# 4095
Total Assets (TTM) in million	1,825	3,369	1,273	1,425	1,437
Seq. Total Assets Change	-45.84 %	164.57 %	-10.6 %	-0.88 %	17.23 %
Seq. Net Income Change	-	-	-	-	-

CYTK's 5 Years Annual ROA >> Back to CYTK Management Effectiveness >> Compare CYTK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 269
Sector	# 606
Overall	# 4001

Return On Assets Statistics
High	Average	Low
12.02 %	-40.56 %	-67.32 %
(Dec 31 2016)		(Mar 31 2024)

Financial Statements
Cytokinetics Incorporated's Assets	$ 1,825 million	CYTK's Balance sheet
Cytokinetics Incorporated's Income	$ -190 million	Quarterly CYTK's Income Statement
CYTK's Income by Division		See CYTK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	25.43 %	69.97 %	-18.71 %	20.69 %	57.61 %
Total Assets in million	1,760	1,403	825	1,015	841
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-785	-590	-526	-389	-215
Annual Return On Assets	-44.61 %	-42.02 %	-63.76 %	-38.31 %	-25.59 %

CYTK's 5 Years Annual ROA >> Back to CYTK Management Effectiveness >> Compare CYTK ROA to its Competitors

More Return On Assets Ratios
CYTK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CYTK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CYTK's Competitors
Subscribers only: Roa for Cytokinetics Incorporated's Suppliers
Subscribers only: Return On Assets for CYTK's Customers

You may also want to know
CYTK's Roi	CYTK's Inventory Turnover Ratio	CYTK's Growth Rates	CYTK's Dividend Comparisons
	CYTK's Profitability Ratios	CYTK's Asset Turnover Ratio	CYTK's Dividend Growth
CYTK's Roe	CYTK's Valuation Ratios	CYTK's Financial Strength Ratios	CYTK's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector

ROA

Date modified: 2026-11-05T09:33:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.